## Table S1. Unadjusted Cox regression analysis investigating predictors of primary endpoint

|  |  |
| --- | --- |
|  | Primary endpoint |
| HR | 95% CI | *P* value |
| Age, per 1 years | 1.220 | 1.019-1.461 | 0.030 |
| Gender, male as reference | 1.036 | 1.026-1.046 | < 0.001 |
| BMI, per 1 kg/m2 | 1.031 | 1.004-1.058 | 0.023 |
| WC, per 1 cm | 1.034 | 1.028-1.041 | < 0.001 |
| Heart rate, per 1 bpm | 1.007 | 0.999-1.015 | 0.089 |
| SBP, per 1 mmHg | 1.007 | 1.002-1.012 | 0.010 |
| DBP, per 1 mmHg | 1.000 | 0.991-1.008 | 0.914 |
| Smoking history | 0.927 | 0.783-1.097 | 0.378 |
| Drinking history | 0.853 | 0.694-1.049 | 0.132 |
| Family history of CAD | 1.047 | 0.798-1.375 | 0.738 |
| Diabetes | 1.448 | 1.222-1.716 | < 0.001 |
| Hypertension | 1.269 | 1.062-1.517 | 0.009 |
| Hyperlipidemia | 2.341 | 1.684-3.255 | < 0.001 |
| Previous MI | 2.273 | 1.905-2.711 | < 0.001 |
| Previous PCI  | 1.757 | 1.445-2.136 | < 0.001 |
| Previous stroke | 1.926 | 1.551-2.390 | < 0.001 |
| Previous PAD | 1.192 | 0.771-1.844 | 0.430 |
| TG, per 1 mmol/L | 1.546 | 1.433-1.668 | < 0.001 |
| TC, per 1 mmol/L | 1.108 | 1.025-1.097 | 0.009 |
| LDL-C, per 1 mmol/L | 1.031 | 0.939-1.132 | 0.521 |
| HDL-C, per 1 mmol/L | 0.324 | 0.218-0.481 | < 0.001 |
| hs-CRP, per 1 mg/L | 1.012 | 1.000-1.025 | 0.057 |
| Creatinine, per 1 μmol/L | 1.005 | 1.000-1.010 | 0.048 |
| eGFR, per 1 mL/(min × 1.73m2) | 0.991 | 0.987-0.996 | < 0.001 |
| Uric acid, μmol/L | 1.000 | 0.999-1.001 | 0.727 |
| FBG, per 1 mmol/L | 1.116 | 1.083-1.149 | < 0.001 |
| HbA1c, per 1% | 1.263 | 1.193-1.337 | < 0.001 |
| LVEF, per 1% | 0.961 | 0.951-0.972 | < 0.001 |
| ACEI/ARB at admission | 1.225 | 1.011-1.486 | 0.038 |
| DAPT at admission | 1.260 | 1.057-1.504 | 0.010 |
| Aspirin at admission | 1.200 | 1.013-1.421 | 0.035 |
| P2Y12 inhibitors at admission | 1.264 | 1.062-1.504 | 0.008 |
| Statins at admission | 1.066 | 0.891-1.276 | 0.485 |
| OHA at admission | 1.313 | 1.072-1.608 | 0.008 |
| Insulin at admission | 1.618 | 1.270-2.062 | < 0.001 |
| ACEI/ARB at discharge | 1.666 | 1.360-2.042 | < 0.001 |
| DAPT at discharge | 0.430 | 0.060-3.057 | 0.399 |
| Statins at discharge | 1.405 | 0.727-2.715 | 0.312 |
| OHA at discharge | 1.299 | 1.060-1.593 | 0.012 |
| Insulin at discharge | 1.633 | 1.278-2.087 | < 0.001 |
| LM lesion | 2.493 | 1.854-3.353 | < 0.001 |
| Multi-vessel lesion | 2.942 | 2.342-3.696 | < 0.001 |
| In-stent restenosis | 2.382 | 1.810-3.134 | < 0.001 |
| Chronic total occlusion lesion | 2.900 | 2.391-3.516 | < 0.001 |
| SYNTAX score, per 1-point | 1.130 | 1.115-1.146 | < 0.001 |
| LM treatment | 2.270 | 1.542-3.343 | < 0.001 |
| LAD treatment | 1.112 | 0.929-1.330 | 0.246 |
| LCX treatment | 1.338 | 1.129-1.587 | 0.001 |
| RCA treatment | 1.601 | 1.353-1.893 | < 0.001 |
| Complete revascularization | 0.585 | 0.495-0.692 | < 0.001 |
| Number of DES, per 1 DES | 1.255 | 1.185-1.329 | < 0.001 |

*BMI* body mass index, *WC* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *CAD* coronary artery disease, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *PAD* peripheral artery disease, *TG* triglyceride, *TC* total cholesterol, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* high-density lipoprotein cholesterol, *hs-CRP* high-sensitivity C-reactive protein, *eGFR* estimated glomerular filtration rate, *FBG* fasting blood glucose, *HbA1c* glycosylated hemoglobin A1c, *LVEF* left ventricular ejection fraction, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin receptor blocker, *DAPT* dual antiplatelet therapy, *OHA* oral hypoglycemic agents, *LM* left main artery, *SYNTAX* synergy between PCI with taxus and cardiac surgery, *LAD* left anterior descending artery, *LCX* left circumflex artery, *RCA* right coronary artery, *DES* drug-eluting stent